Trevi Therapeutics, Inc. - Common Stock (TRVI)
CUSIP: 89532M101
Q3 2022 13F Holders as of 30 Sep 2022
- Type / Class
- Equity / Common Stock
- Shares outstanding
- 128,120,714
- Total 13F shares
- 45,770,959
- Share change
- +17,019,628
- Total reported value
- $70,490,000
- Price per share
- $1.54
- Number of holders
- 37
- Value change
- +$26,192,291
- Number of buys
- 23
- Number of sells
- 12
Quarterly Holders Quick Answers
What is CUSIP 89532M101?
CUSIP 89532M101 identifies TRVI - Trevi Therapeutics, Inc. - Common Stock in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 89532M101:
Top shareholders of TRVI - Trevi Therapeutics, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| NEA Management Company, LLC |
13F
|
Company |
8.9%
|
11,373,174
|
$31,959,000 | — | 30 Jun 2022 | |
| TPG GP A, LLC |
13F
3/4/5
|
Company · Former 10% Owner |
3.4%
|
4,324,883
|
$12,153,000 | — | 30 Jun 2022 | |
| VR Adviser, LLC |
13F
|
Company |
2.4%
|
3,050,022
|
$8,571,000 | — | 30 Jun 2022 | |
| MAI Capital Management |
13F
|
Company |
1.6%
|
2,040,009
|
$5,732,000 | — | 30 Jun 2022 | |
| Rubric Capital Management LP |
13F
|
Company |
1.4%
|
1,778,420
|
$4,997,000 | — | 30 Jun 2022 | |
| Fairmount Funds Management LLC |
13F
|
Company |
1.3%
|
1,624,389
|
$4,565,000 | — | 30 Jun 2022 | |
| Altium Capital Management LLC |
13F
|
Company |
1%
|
1,284,000
|
$3,608,000 | — | 30 Jun 2022 | |
| Frazier Life Sciences Management, L.P. |
13F
|
Company |
0.91%
|
1,171,627
|
$3,292,000 | — | 30 Jun 2022 | |
| Peter W. Sonsini |
3/4/5
|
10%+ Owner |
—
mixed-class rows
|
3,948,948
mixed-class rows
|
$1,916,875 | — | 11 Apr 2022 | |
| ARMISTICE CAPITAL, LLC |
13F
|
Company |
0.32%
|
416,000
|
$1,169,000 | — | 30 Jun 2022 | |
| Informed Momentum Co LLC |
13F
|
Company |
0.29%
|
373,243
|
$1,049,000 | — | 30 Jun 2022 | |
| VANGUARD GROUP INC |
13F
|
Company |
0.18%
|
236,940
|
$666,000 | — | 30 Jun 2022 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.15%
|
195,146
|
$548,000 | — | 30 Jun 2022 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.12%
|
151,500
|
$426,000 | — | 30 Jun 2022 | |
| J. Goldman & Co LP |
13F
|
Company |
0.11%
|
135,000
|
$379,000 | — | 30 Jun 2022 | |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.08%
|
102,600
|
$288,000 | — | 30 Jun 2022 | |
| WealthTrust Axiom LLC |
13F
|
Company |
0.07%
|
93,500
|
$262,000 | — | 30 Jun 2022 | |
| FMR LLC |
13F
|
Company |
0.06%
|
83,225
|
$234,000 | — | 30 Jun 2022 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.05%
|
66,183
|
$186,000 | — | 30 Jun 2022 | |
| BlackRock Finance, Inc. |
13F
|
Company |
0.04%
|
57,494
|
$161,000 | — | 30 Jun 2022 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.04%
|
46,298
|
$130,000 | — | 30 Jun 2022 | |
| STATE STREET CORP |
13F
|
Company |
0.03%
|
39,842
|
$112,000 | — | 30 Jun 2022 | |
| ACUTA CAPITAL PARTNERS, LLC |
13F
|
Company |
0.03%
|
35,000
|
$98,000 | — | 30 Jun 2022 | |
| UNITED BANK |
13F
|
Company |
0.02%
|
28,450
|
$80,000 | — | 30 Jun 2022 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.01%
|
12,557
|
$36,000 | — | 30 Jun 2022 | |
| LPL Financial LLC |
13F
|
Company |
0.01%
|
10,000
|
$28,000 | — | 30 Jun 2022 | |
| FNY Investment Advisers, LLC |
13F
|
Company |
0.01%
|
7,986
|
$22,000 | — | 30 Jun 2022 | |
| UBS Group AG |
13F
|
Company |
0%
|
4,771
|
$13,000 | — | 30 Jun 2022 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0%
|
3,874
|
$11,000 | — | 30 Jun 2022 | |
| FIRST MANHATTAN CO. LLC. |
13F
|
Company |
0%
|
2,500
|
$7,000 | — | 30 Jun 2022 | |
| CITIGROUP INC |
13F
|
Company |
0%
|
1,700
|
$5,000 | — | 30 Jun 2022 | |
| Curi Wealth Management, LLC |
13F
|
Company |
0%
|
998
|
$3,000 | — | 30 Jun 2022 | |
| William P. Forbes |
3/4/5
|
Chief Development Officer |
—
mixed-class rows
|
185,500
mixed-class rows
|
— | — | 29 Jun 2022 |
Institutional Holders of Trevi Therapeutics, Inc. - Common Stock (TRVI) as of Q3 2022
As of 30 Sep 2022,
Trevi Therapeutics, Inc. - Common Stock (TRVI) was held by
37 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
45,770,959 shares.
The largest 10 holders included
NEA Management Company, LLC, Fairmount Funds Management LLC, Rubric Capital Management LP, Frazier Life Sciences Management, L.P., VIKING GLOBAL INVESTORS LP, VR Adviser, LLC, MAI Capital Management, FMR LLC, VANGUARD GROUP INC, and Altium Capital Management LP.
This page lists
37
institutional shareholders reporting positions in this security
for the Q3 2022 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q3 2022 vs Q2 2022 Across Filers
Q2 2022 holders
31
Q3 2022 holders
37
Holder diff
6
| Investor | Q2 2022 Shares | Q3 2022 Shares | Share Diff | Share Chg % | Q2 2022 Value $ | Q3 2022 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.